Phase 2 N=16 Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
Uveal Melanoma With Liver Metastases
Primary: Objective Response Rate (ORR) — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=58 GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases
Melanoma · Brain Metastases
Primary: 1-year Survival Rate — 31.8 Percentage of patients alive at 1 year
Phase 2 N=14 Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Metastatic Malignant Neoplasm in the Liver · Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) — 0; 0; 8; 5 Participants
Phase 2 N=38 Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Ciliary Body and Choroid Melanoma, Medium/Large Size · Ciliary Body and Choroid Melanoma, Small Size · Iris Melanoma
Primary: Number of Patients With Disease-free Survival (DFS) — 8 Participants
Phase 2 N=98 Melanoma Vaccine With Peptides and Leuprolide
Melanoma
Primary: Number of Participants With T-cell Response to Peptide Vaccine — 6; 1; 12; 19 Participants
Phase 2 N=53 Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Uveal Melanoma · Liver Metastases
Primary: Response of Liver Metastases — 0; 0; 5; 3 participants
Phase 2 N=48 SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Stage IV Uveal Melanoma
Primary: Clinical Benefit Rate of Previously Treated and Naive Patients — 0; 0; 7; 6 Participants
N/A N=171 Shear Wave Sonoelastography in Pediatric Liver Fibrosis
Sonoelastography · Elastography · Elastograms
Primary: 2D-SWE Measurements' Capability of Predicting Stages of Fibrosis Based on METAVIR Scoring System — NA; 96.9; 95.2; 1.00 percentage of exams
N/A N=368 Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors
Melanoma (Skin)
Primary: Sun Protection Habits Index — 2.9; 3 scores on a scale
Phase 2 N=80 A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Metastatic Melanoma
Primary: Intracranial Objective Response Rate (ORR) — 46.4 Percentage of participants
N/A N=231 Diagnostic Precision of the AI Tool Dermalyzer to Identify Malignant Melanomas in Subjects Seeking Primary Care for Melanoma-suspected Cutaneous Lesions
Malignant Melanoma
Primary: Diagnostic Accuracy to Detect Melanoma — 20; 92; 1; 140 number of skin lesions
Phase 2 N=22 Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E
Fatty Liver
Primary: Biochemical: Number of Patients With Normal Transaminases at End of Treatment. — 6; 6; 6 Participants
N/A N=2,600 Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Liver Failure, Acute on Chronic
Primary: 28-day Mortality,28-day Liver-transplantation Free Mortality& 28-day Liver Transplantation Rate — 74; 124; 74 Participants
N/A N=48 Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
Hepatitis C, Chronic · Non-Alcoholic Fatty Liver Disease
Primary: Cholate Shunt Test — 28.0; 37.6; 33.4 SHUNT %
N/A N=6 Assess the Feasibility of Cone Beam CT to Localize Liver Metastases Immediately Prior to Radiotherapy
Localize Liver Metastases
Primary: Number of Participants Eligible for Cone Beam Tumor Localization" — 5 participants